Tigecycline Dosing in Renal Impairment
No dose adjustment of tigecycline is required for patients with renal impairment, including those on hemodialysis or continuous renal replacement therapy (CRRT). 1
Standard Dosing Regimen
The FDA-approved dosing for tigecycline remains unchanged regardless of renal function 1:
- Loading dose: 100 mg IV
- Maintenance dose: 50 mg IV every 12 hours
- Infusion time: 30-60 minutes
Evidence Supporting No Renal Dose Adjustment
Pharmacokinetic Rationale
- Renal clearance accounts for only approximately 20% of total tigecycline systemic clearance in patients with normal renal function 2
- In patients with severe renal impairment (creatinine clearance <30 mL/min), tigecycline clearance is reduced by only ~20%, with AUC increased by ~30% 2
- These modest changes do not warrant dose modification 2, 3
Dialysis Considerations
Hemodialysis patients: Tigecycline is not efficiently removed by dialysis and can be administered without regard to timing of hemodialysis sessions 2, 3, 4
CRRT patients: Despite high dialysability (saturation coefficients of 0.79 for CVVHD and 0.90 for CVVHDF), the contribution of CRRT to tigecycline clearance is moderate (CRRT clearance 1.69-2.71 L/h) compared to physiological clearance (18.3 L/h) 5. No dose adjustment is necessary for patients receiving CRRT 5.
Important Caveats and Considerations
Hepatic Impairment Requires Adjustment
While renal function does not affect dosing, severe hepatic impairment (Child-Pugh C) requires dose reduction 1:
- Loading dose: 100 mg (unchanged)
- Maintenance dose: 25 mg every 12 hours (reduced from 50 mg)
- No adjustment needed for mild-moderate hepatic impairment (Child-Pugh A or B) 1
Higher Doses May Be Needed for Specific Infections
Standard dosing may be inadequate for certain clinical scenarios 6, 7:
- Hospital-acquired pneumonia/VAP: Higher dosing regimens (200 mg loading dose followed by 100 mg q12h) should be considered, as standard doses achieve suboptimal lung concentrations 7
- Bloodstream infections: Standard tigecycline dosing is generally inadequate; alternative agents are preferred 7
- Complicated UTI: Tigecycline is inferior to aminoglycosides and should be avoided 6
Critical Illness Considerations
In critically ill patients, APACHE II score and age affect tigecycline pharmacokinetics 8. For severe infections with MIC ≥2 mg/L, standard dosing often fails to achieve adequate PK/PD targets, and dose escalation or alternative therapy should be considered 9, 8.
Black Box Warning
Tigecycline carries an FDA black box warning for increased all-cause mortality (0.6% absolute risk increase) and should be reserved for situations when alternative treatments are not suitable 1.